Ten-Year Data From Roche's Breast Cancer Trial Shows Perjeta-Based Regimen Cuts Death Risk By 17%

Roche Holdings AG (OTC:RHHBY) on Tuesday released statistically significant final overall survival (OS) results from the phase III APHINITY study in people with human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer. After ten years, the risk of death was reduced by 17%…